Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / Spira 80-marker panel plus clinical factors

Spira 80-marker panel plus clinical factors



QA State: Curated
Short Name:
HGNC Name:

This clinicogenomic model incorporates the gene expression pattern of histologcially normal large airway epithelial cells collected at time of bronchoscopy (see 'Spira 80-marker panel for lung cancer') with clinical parameters about lung cancer risk.

Panel Details

No member markers defined for this panel.


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Curated


The Spira 80-marker panel for lung cancer biomarker was developed by using the gene expression patterns obtained from cytologically normal large airway epithelial cells from smokers undergoing bronchoscopy for suspiction of lung cancer. The results from the bronchosopy are 100% specific for lung cancer, but has a limited sensitivity of 30-80% depending ont he stage and location of the cancer. Therefore, difficult decisions must be made regarding care and treatment of patients with potentially early-stage, treatable, curable cancers. By adding the clinical factors to the 80-marker panel, the predictive nature of the model has been improved.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated resources found.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.